Urology San Diego — Oceanside, California

Urology San Diego is a clinical research site located in Oceanside, California, United States 92056.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Urology San Diego has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Bladder Cancer, Urothelial Carcinoma (UC), Hematuria.

Sponsors: Convergent Genomics, Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Oceanside

Browse all research sites in California · View every site in Oceanside

• Naval Hospital Camp Pendelton
• Naval Hospital Campe Pendleton
• Sharp Memorial Hospital
• Naval Hospital Camp Pendleton
• Excell Research
• Dermatology Specialists
• Research Site
• North County Clinical Research
• Pfizer Investigational Site
• Alkermes Investigational Site
• Novartis Investigative Site
• GSK Investigational Site

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Urology San Diego?

Urology San Diego has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Urology San Diego conducted?

Urology San Diego has 1 clinical trials on record, with 1 currently active. Their work covers Bladder Cancer, Urothelial Carcinoma (UC), Hematuria.

Is Urology San Diego accredited by Crixeo Clinical Trials?

Urology San Diego has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Urology San Diego?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.